114 related articles for article (PubMed ID: 35307155)
1. Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease.
Saenz-Pipaon G; Ravassa S; Larsen KL; Martinez-Aguilar E; Orbe J; Rodriguez JA; Fernandez-Alonso L; Gonzalez A; Martín-Ventura JL; Paramo JA; Lindholt JS; Roncal C
Eur J Vasc Endovasc Surg; 2022 Apr; 63(4):648-656. PubMed ID: 35307155
[TBL] [Abstract][Full Text] [Related]
2. Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD).
Saenz-Pipaon G; San Martín P; Planell N; Maillo A; Ravassa S; Vilas-Zornoza A; Martinez-Aguilar E; Rodriguez JA; Alameda D; Lara-Astiaso D; Prosper F; Paramo JA; Orbe J; Gomez-Cabrero D; Roncal C
J Extracell Vesicles; 2020; 9(1):1729646. PubMed ID: 32158521
[TBL] [Abstract][Full Text] [Related]
3. Role of LCN2 in a murine model of hindlimb ischemia and in peripheral artery disease patients, and its potential regulation by miR-138-5P.
Saenz-Pipaon G; Jover E; van der Bent ML; Orbe J; Rodriguez JA; Fernández-Celis A; Quax PHA; Paramo JA; López-Andrés N; Martín-Ventura JL; Nossent AY; Roncal C
Atherosclerosis; 2023 Nov; 385():117343. PubMed ID: 37871404
[TBL] [Abstract][Full Text] [Related]
4. Association of calprotectin with other inflammatory parameters in the prediction of mortality for ischemic stroke.
Marta-Enguita J; Navarro-Oviedo M; Rubio-Baines I; Aymerich N; Herrera M; Zandio B; Mayor S; Rodriguez JA; Páramo JA; Toledo E; Mendioroz M; Muñoz R; Orbe J
J Neuroinflammation; 2021 Jan; 18(1):3. PubMed ID: 33402185
[TBL] [Abstract][Full Text] [Related]
5. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
[TBL] [Abstract][Full Text] [Related]
6. Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study.
Zollner A; Schmiderer A; Reider SJ; Oberhuber G; Pfister A; Texler B; Watschinger C; Koch R; Effenberger M; Raine T; Tilg H; Moschen AR
J Crohns Colitis; 2021 Jan; 15(1):43-54. PubMed ID: 32556317
[TBL] [Abstract][Full Text] [Related]
7. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
[TBL] [Abstract][Full Text] [Related]
8. Plasma Extracellular Vesicle Serpin G1 and CD14 Levels are Associated with Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients Undergoing Femoral Endarterectomy.
Verwer MC; Mekke JM; Timmerman N; Van Der Pol QY; Frissen C; Pasterkamp G; De Borst GJ; Hazenberg CEVB; De Kleijn DPV
Eur J Vasc Endovasc Surg; 2023 Feb; 65(2):282-290. PubMed ID: 36334903
[TBL] [Abstract][Full Text] [Related]
9. Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury.
Westhoff JH; Seibert FS; Waldherr S; Bauer F; Tönshoff B; Fichtner A; Westhoff TH
Eur J Pediatr; 2017 Jun; 176(6):745-755. PubMed ID: 28409285
[TBL] [Abstract][Full Text] [Related]
10. The Role of Circulating Biomarkers in Peripheral Arterial Disease.
Saenz-Pipaon G; Martinez-Aguilar E; Orbe J; González Miqueo A; Fernandez-Alonso L; Paramo JA; Roncal C
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808453
[TBL] [Abstract][Full Text] [Related]
11. Significance of S100A8, S100A9 and calprotectin levels in bladder cancer.
Yasar O; Akcay T; Obek C; Turegun FA
Scand J Clin Lab Invest; 2017 Oct; 77(6):437-441. PubMed ID: 28609200
[TBL] [Abstract][Full Text] [Related]
12. Calprotectin and Neutrophil Gelatinase-Associated Lipocalin As Biomarkers of Acute Kidney Injury in Acute Coronary Syndrome.
Zhen XW; Song NP; Ma LH; Ma LN; Guo L; Yang XD
Am J Med Sci; 2021 Jun; 361(6):736-743. PubMed ID: 33892917
[TBL] [Abstract][Full Text] [Related]
13. Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients.
Pedersen L; Nybo M; Poulsen MK; Henriksen JE; Dahl J; Rasmussen LM
BMC Cardiovasc Disord; 2014 Dec; 14():196. PubMed ID: 25527236
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of Urinary Calprotectin after Renal Ischaemia.
Ebbing J; Seibert FS; Pagonas N; Bauer F; Miller K; Kempkensteffen C; Günzel K; Bachmann A; Seifert HH; Rentsch CA; Ardelt P; Wetterauer C; Amico P; Babel N; Westhoff TH
PLoS One; 2016; 11(1):e0146395. PubMed ID: 26745147
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study.
Sigvant B; Hasvold P; Kragsterman B; Falkenberg M; Johansson S; Thuresson M; Nordanstig J
J Vasc Surg; 2017 Aug; 66(2):507-514.e1. PubMed ID: 28433332
[TBL] [Abstract][Full Text] [Related]
16. The value of calprotectin S100A8/A9 complex as a biomarker in colorectal cancer: A systematic review.
Moris D; Spartalis E; Angelou A; Margonis GA; Papalambros A; Petrou A; Athanasiou A; Schizas D; Dimitroulis D; Felekouras E
J BUON; 2016; 21(4):859-866. PubMed ID: 27685906
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
Bonaca MP; Wiviott SD; Zelniker TA; Mosenzon O; Bhatt DL; Leiter LA; McGuire DK; Goodrich EL; De Mendonca Furtado RH; Wilding JPH; Cahn A; Gause-Nilsson IAM; Johanson P; Fredriksson M; Johansson PA; Langkilde AM; Raz I; Sabatine MS
Circulation; 2020 Aug; 142(8):734-747. PubMed ID: 32795086
[TBL] [Abstract][Full Text] [Related]
18. Lipocalin 2 expression is associated with aggressive features of endometrial cancer.
Mannelqvist M; Stefansson IM; Wik E; Kusonmano K; Raeder MB; Øyan AM; Kalland KH; Moses MA; Salvesen HB; Akslen LA
BMC Cancer; 2012 May; 12():169. PubMed ID: 22559235
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.
Chapuis N; Ibrahimi N; Belmondo T; Goulvestre C; Berger AE; Mariaggi AA; Andrieu M; Chenevier-Gobeaux C; Bayle A; Campos L; Cheurfa C; Chocron R; Diehl JL; Doumenc B; Duchemin J; Duprat M; François F; Gendron N; Mirault T; Pène F; Philippe A; Pommeret F; Sanchez O; Smadja DM; Szwebel TA; Silvin A; Ginhoux F; Lacroix L; Jules-Clément G; Rapeteramana S; Mavier C; Steller L; Perniconi B; André F; Drubay D; Fontenay M; Hüe S; Paul S; Solary E
EBioMedicine; 2022 Jun; 80():104077. PubMed ID: 35644124
[TBL] [Abstract][Full Text] [Related]
20. Elevated level of circulating calprotectin correlates with severity and high mortality in patients with COVID-19.
Zhang H; Zhang Q; Liu K; Yuan Z; Xu X; Dong J
Immun Inflamm Dis; 2024 Mar; 12(3):e1212. PubMed ID: 38477671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
